Search
Eplerenone
go.drugbank.com/drugs/DB00700ApprovedInvestigationalregulatory feedback of aldosterone on renin secretion. … Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative
Products: EPLERENON AL 25MG FTA, EPLERENON AL 50MG FTAGinkgo biloba
go.drugbank.com/drugs/DB01381ApprovedInvestigationalNutraceutical[A232389] Most of the studies that investigate the effect of _ginkgo biloba_ use the standardized extract of _Ginkgo biloba_ (EGb) 761 (EGb761), which was developed by a German pharmaceutical company in … [A232384] _Ginkgo biloba_ was investigated in preliminary studies for a variety of therapeutic purposes such as improving cardiovascular health, sexual dysfunction, psychiatric disorders, skin disorders
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesProducts: GINKGO AL 40 MG FTA, GINKGO AL 80 MG FTAMefloquine
go.drugbank.com/drugs/DB00358ApprovedMalaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. … The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019.
Trilaciclib
go.drugbank.com/drugs/DB15442ApprovedInvestigationalTrilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing … [L31828] CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy.[A229323] Trilaciclib was first described in the literature in 2016.
Belatacept
go.drugbank.com/drugs/DB06681ApprovedInvestigationalIt is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. … FDA approved on June 15, 2011.
Triflusal
go.drugbank.com/drugs/DB08814ApprovedWithdrawnTriflusal is a 2-acetoxy-4-trifluoromethylbenzoic acid and it is an aspirin chemically-related molecule but not a derivative. … Uriach and Company and even though it is commercialized in different countries it is not approved by the FDA, EMA or HealthCanada.
Dichlorobenzyl alcohol
go.drugbank.com/drugs/DB13269ApprovedDichlorobenzyl alcohol is a mild antiseptic with a broad spectrum for bacterial and virus associated with mouth and throat infections. … [A33047] Dichlorobenzyl alcohol is considered as an active ingredient found in several marketed OTC products by Health Canada which has categorized this agent as an anatomical therapeutic chemical.
Follitropin
go.drugbank.com/drugs/DB00066ApprovedInvestigationalwith significantly higher estradiol (E2) levels. … However, a more recent study showed there is may be a slight clinical difference, with the alpha form tending towards a higher pregnancy rate and the beta form tending towards a lower pregnancy rate, but
Synonyms: FSH-aProducts: REKOVELLE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 12MCG/0.36ML, REKOVELLE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 72MCG/2.16MLRanibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigationalRanibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology … BYOOVIZ, a biosimilar of LUCENTIS, was approved by Health Canada in March 2022, making it the first and only biosimilar drug of ranibizumab available in Canada.
Products: LUCENTIS 10 MG/ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE, LUCENTIS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 1.65mg/0.165mlVibegron
go.drugbank.com/drugs/DB14895ApprovedInvestigational[L28305] Vibegron was first approved in Japan in September 2018 for the treatment of overactive bladder,[A226050] a condition associated with distressing symptoms of urge urinary incontinence, urgency, … On December 23, 2020, vibegron was approved for the same indication in adults. It is available as oral tablets under the market name GEMTESA.